´ëÇÑ°£¾ÏÇÐȸ Á¦14Â÷ Á¤±âÇмú´ëȸ : 2020-02-21±³À°ÀÏÀÚ : 2020-02-21
±³À°Àå¼Ò : ±×·£µå ÀÎÅÍÄÁƼ³ÙÅ» ¼¿ï Æĸ£³ª½º 5Ãþ ±×·£µåº¼·ë
±³À°ÁÖÁ¦ :
´ëÇÑ°£¾ÏÇÐȸ Á¦14Â÷ Á¤±âÇмú´ëȸÁÖÃÖ±â°ü : ´ëÇÑ°£¾ÏÇÐȸ
´ã´çÀÚ : ÀÌÁøÈ Â÷Àå
¿¬¶ôó : 02-373-1005
À̸ÞÀÏ :
jhlee@hbni.co.kr ±³À°Á¾·ù : ³»°ú, ¿Ü°ú
Âü¼®¿¹»óÀοø : 500¸í
Èñ¸ÁÆòÁ¡ : 6Á¡
Áö¿ª :
¼¿ïƯº°½Ã±³À°½Ã°£ : 8 ½Ã°£ 40ºÐ
¼¼ºÎ¼ö°·á : 50,000¿ø
ºñ°í Æò»ýȸ¿ø 4¸¸¿ø, ºñȸ¿ø5¸¸¿ø, Àü°øÀÇ/±ºÀÇ°ü/°£È£»ç 2¸¸¿ø (»çÀüµî·Ï)
±¸ºÐ ¿ùÀÏ °ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 02-21 ±×·£µåº¼·ë 08:30~09:30 Session 1. Plenary Session - Invited Papers ¹ÌÁ¤(¼ö»óÀÚ ¿¹Á¤)(¹ÌÁ¤)
ÈÞ½Ä 02-21 ±×·£µåº¼·ë 09:30~09:50 ÈÞ½Ä ()
±³À°½Ã°£ 02-21 ±×·£µåº¼·ë 09:50~10:10 Personalized Risk-based Surveillance for HCC ÀåÀº¼±(¼¿ïÀÇ´ë)
±³À°½Ã°£ 02-21 ±×·£µåº¼·ë 10:10~10:30 Surveillance Strategy for HCC Following Curative Intent Treatment ÇÑ´ëÈÆ(¿¬¼¼ÀÇ´ë)
±³À°½Ã°£ 02-21 ±×·£µåº¼·ë 10:30~10:50 HCC Surveillance Using Imaging Modalities Beyond US ±è¼Ò¿¬(¿ï»êÀÇ´ë)
±³À°½Ã°£ 02-21 ±×·£µåº¼·ë 10:50~11:10 Clinical Significance of Tumor Markers in HCC: AFP, PIVKA-II and AFP-L3 ÀÓ¿µ¼®(¿ï»êÀÇ´ë)
±âŸ 02-21 ±×·£µåº¼·ë 11:10~11:20 ÃÑȸ ()
±³À°½Ã°£ 02-21 ±×·£µåº¼·ë 11:20~11:40 Opportunities in Biomaterial for the Treatment of HCC Dong-Hyun Kim(Northwestern Univ., USA)
±³À°½Ã°£ 02-21 ±×·£µåº¼·ë 11:40~12:00 Current Clinical Topics of Intrahepatic Cholangiocarcinoma in Japan Shoji Kubo(President, LCSGJ)
±³À°½Ã°£ 02-21 ±×·£µåº¼·ë 12:00~13:00 Synergistic Effect of Immune Checkpoint Inhibitor and Anti-angiogenic Agent for HCC Treatment Ann-Lii Cheng(National Taiwan Univ)
±³À°½Ã°£ 02-21 ±×·£µåº¼·ë 13:00~14:00 HCC with Oligometastasis at Initial Presentation ÃÖÁ¾±â&±è°¸ð (Case), ±è»ó±Õ (³»°ú), ÁÖµ¿Áø (¿Ü°ú), À±»ó¹Î (¹æ»ç¼±Á¾¾çÇаú), ±è°æ¹Î (¿µ»óÀÇÇаú)(¿ï»êÀÇ´ë, ¼øõÇâÀÇ´ë, ¿¬¼¼ÀÇ´ë, ¿ï»êÀÇ´ë, ¿¬¼¼ÀÇ´ë)
±³À°½Ã°£ 02-21 ±×·£µåº¼·ë 14:00~14:20 Comparison of Guidelines for Non-invasive Diagnosis of HCC ÀÌÁ¤¹Î(¼¿ïÀÇ´ë)
±³À°½Ã°£ 02-21 ±×·£µåº¼·ë 14:20~14:40 Current Evidences and Future Perspectives of Targeted Therapies and Immune Checkpoint Inhibitors Á¶¼º¹ü(Àü³²ÀÇ´ë)
±³À°½Ã°£ 02-21 ±×·£µåº¼·ë 14:40~15:00 Recommended and Extended Indications of Surgical Resection for HCC ÃÖ±Ô¼º(¼º±Õ°üÀÇ´ë)
±³À°½Ã°£ 02-21 ±×·£µåº¼·ë 15:00~15:20 How To Expand the Role of Radiotherapy in HCC Á¤ÁøÈ«(¿ï»êÀÇ´ë)
±³À°½Ã°£ 02-21 ±×·£µåº¼·ë 15:20~16:20 Poster Presentation äÅÃÀÚ ¿Ü()
±³À°½Ã°£ 02-21 ±×·£µåº¼·ë 16:20~16:40 Microwave Ablation vs. Radiofrequency Ablation vs. Cryoablation in Early Stage HCC À̹οì(¼º±Õ°üÀÇ´ë)
±³À°½Ã°£ 02-21 ±×·£µåº¼·ë 16:40~17:00 Transarterial Radioembolization for HCC: Indications, Patient Selection and Outcomes ±èÀ±ÁØ(¼¿ïÀÇ´ë)
±³À°½Ã°£ 02-21 ±×·£µåº¼·ë 17:00~17:20 When Do We Select Photon Beam or Particle Beam Radiotherapy? ¹ÚÈñö(¼º±Õ°üÀÇ´ë)
±³À°½Ã°£ 02-21 ±×·£µåº¼·ë 17:20~17:40 Stretching the Limits of Laparoscopic Surgery in HCC ±è±âÈÆ(¿ï»êÀÇ´ë)